search
Back to results

Intercostal Nerve Cryoablation Versus Epidural Analgesia for Nuss Repair of Pectus Excavatum (ICE)

Primary Purpose

Pectus Excavatum, Funnel Chest

Status
Not yet recruiting
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
Intercostal nerve cryoablation
Thoracic epidural analgesia (continuous infusion with sufentanyl (1 µg/ml) and bupivacaine (1.25 mg/ml))
Intercostal nerve block (single shot bupivacaine (1.25 mg/ml))
Opioids (oxycodone with prolonged discharge 10 mg PO every 12 hours and oxycodone 5 mg every 6 hours, as needed)
Sponsored by
Zuyderland Medisch Centrum
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Pectus Excavatum focused on measuring Pectus Excavatum, Funnel Chest, Intercostal nerve cryoablation, Analgesia

Eligibility Criteria

12 Years - 24 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients undergoing the minimal invasive Nuss procedure for surgical repair of pectus excavatum. Young patients (12-24 years of age) according to the definition used by the World Health Organization. This cut-off point is chosen to create a more homogenous patient sample, as the thoracic cage is fully matured by the age of 24, in size and density, which will have an effect on postoperative pain. Exclusion Criteria: A chest wall deformity other than pectus excavatum; Opioid use in the 3 months prior to surgery; Pain syndrome (e.g., fibromyalgia) or neuropathic pain prior to surgical repair of pectus excavatum; Connective tissue disease (e.g., Marfan syndrome, Ehlers-Danlos syndrome); Previous thoracic surgery or pectus excavatum repair; Contraindication for intercostal nerve cryoablation or thoracic epidural analgesia (e.g., patient refusal, infection at the site of cannulation, uncontrolled systemic infection, bleeding diathesis, increased intracranial pressure, mechanical spine obstruction); Psychiatric disease currently receiving treatment; Not mastering the Dutch language; Participation in another clinical trial that may interfere with the current trial.

Sites / Locations

  • Zuyderland Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Intercostal nerve cryoablation

Thoracic epidural (local continuous infusion with sufentanyl (1 µg/ml) and bupivacaine (1.25 mg/ml))

Arm Description

When a patient is allocated to the intercostal nerve cryoablation group, cryoablation will be performed prior to bar placement. In brief, cryoablation will be performed at the level of the bar and two levels above and below, bilaterally. For this, a second portal access will be placed for video guidance on the contralateral side, and the cryoprobe (cryoICE, Atricure, Masion, OH, USA) will be inserted through the thoracic incisions that are already made for bar placement. The probe will be placed at the inferior aspect of the ribs, posterior to the midaxillary line, directly on the neurovascular bundle. One freezing cycle takes 2 minutes, and a temperature of -60 ⁰C will be applied. The probe will be warmed to room temperature before removing it from the pleura to prevent additional trauma. Furthermore, intercostal nerve cryoablation will be combined with single shot bupivacaine (1.25 mg/ml) intercostal nerve blocks placed just anterior to the side of the cryoablation.

Prior to surgery, an anesthesiologist will place the thoracic epidural at T5-T6 or T6-T7 interspace in the awake patient. After correct placement, a local continuous infusion with sufentanyl (1 µg/ml) and bupivacaine (1.25 mg/ml) will be started. At the third postoperative day, thoracic epidural analgesia will be ceased and transitioned to oral pain medication at discretion of the pain management team. In general, opioids (oxycodone with prolonged discharge 10 mg PO every 12 hours and oxycodone 5 mg every 6 hours as needed) will be provided 12 hours before thoracic epidural analgesia is ceased.

Outcomes

Primary Outcome Measures

Length of hospital stay
Number of days of hospital admittance after the Nuss procedure.

Secondary Outcome Measures

Pain intensity
Pain intensity at rest and during mobilization. Pain scores will be rated on the numeric rating scale (NRS, 1-10)
Operative time
Operative time in minutes. Duration of cryoablation will be assessed separately. Operative time will not include the time needed for the placement of the thoracic epidural as placement will be performed in the preoperative care unit.
Opioid usage
A) Opioid usage during postoperative day 1 and 2; B) Opioid usage within the first 2 weeks after surgery. Opioid usage will be converted to oral morphine milligram equivalents (MME). Epidural infusion medication does not distribute systematically and therefore cannot be converted to MME. Epidural infusion medication will be omitted in calculation of opioid usage and opioid usage in the Thoracic epidural group will therefore be an underestimation of the actual usage. Upon discharge, patients will be prescribed opioids for 9 days. The need for a refill prescription will be assessed via a telephone appointment.
Procedure- and analgesia-related complications
Procedure- and analgesia-related complications as defined in Supplementary Materials Table 1-2, including neuropathic pain, graded according to the Clavien-Dindo classification.
Intensive care unit admission
Intensive care unit admission due to the occurrence of perioperative complications in absolute numbers
Length of intensive care unit admission
Length of admission due to the occurrence of perioperative complications in absolute numbers.
Number of readmissions
Number of readmissions denoted as absolute numbers.
Length of readmissions
length of readmissions denoted as absolute numbers.
Degree of mobility
Degree of mobility measured on a 4-point scale (i.e., 1. on the bed, 2. to the chair, 3. to the toilet, 4. outside the patient's hospital room) during postoperative day 1 and 2.
HRQOL - PEEQ
HRQOL, measured by the Dutch version of the pectus evaluation questionnaire (PEEQ). The PEEQ is a validated disease specific questionnaire evaluating the quality of life in pectus excavatum patients (37,38).
HRQOL - SF-36
HRQOL, measured by the Dutch version of the short form health survey (SF-36)(37-40). The SF-36 is a generic questionnaire that taps health in eight dimensions (39).
HRQOL - EQ-5D-5L
HRQOL, measured by the Dutch version of the EuroQol 5 dimensions 5 levels (EQ-5D-5L) (37-40). For the EQ-5D-5L, participants will rate their health in 5 dimensions on 5 levels and will give an overall score of their health on a visual analogue scale (VAS) (40).
Days to return to work/school
Days to return to work/school, reported as days between discharge from hospital and return to work or school.
Postoperative visits
Number of postoperative outpatient visits and telephone appointments denoted as absolute numbers in the first 6 months after the surgical procedure.
Hospital costs
Hospital costs, reported as hospital costs during initial hospitalization (e.g., medication, patient care supply, surgical equipment), and hospital costs after discharge until 6 months follow-up (e.g., medications, outpatient visits, (opioid related) readmissions).

Full Information

First Posted
January 26, 2023
Last Updated
February 15, 2023
Sponsor
Zuyderland Medisch Centrum
Collaborators
AtriCure, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT05731973
Brief Title
Intercostal Nerve Cryoablation Versus Epidural Analgesia for Nuss Repair of Pectus Excavatum
Acronym
ICE
Official Title
Intercostal Nerve Cryoablation Versus Thoracic Epidural Analgesia for Minimal Invasive Nuss Repair of Pectus Excavatum: a Randomized Clinical Trial (ICE Trial)
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
March 2023 (Anticipated)
Primary Completion Date
March 2024 (Anticipated)
Study Completion Date
September 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Zuyderland Medisch Centrum
Collaborators
AtriCure, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Primary objective of the current study is to determine the impact of intercostal nerve cryoablation on postoperative length of hospital stay compared to standard pain management of young pectus excavatum patients (12-24 years) treated with the minimal invasive Nuss procedure. The study is designed as a single center, prospective, unblinded, randomized clinical trial.
Detailed Description
Rationale: The minimal invasive Nuss procedure is currently considered the treatment of choice for pectus excavatum. This procedure is usually associated with severe postoperative pain as great forces are employed on the thoracic cage to correct the sternal depression. Pain is the main limiting factor for early discharge. Epidural analgesia is currently considered gold standard for postoperative pain treatment. Alternative pain management strategies (e.g., patient-controlled analgesia and paravertebral nerve block) have also been described but fail in accomplishing adequate prolonged post-operative pain management. Alternatively, continuous use of opioids comes with side-effects like severe nausea, urinary retention and obstipation. Intercostal nerve cryoablation seems a promising novel technique for postoperative analgesia. Prior studies comparing intercostal cryoablation to other pain treatment modalities after pectus excavatum repair through the minimal invasive Nuss procedure report promising results, but pose significant limitations (e.g., small sample size, retrospective nature with non-matched patient groups or considerable confounders). Objective: Primary objective of the current study is to determine the impact of intercostal nerve cryoablation on postoperative length of hospital stay compared to standard pain management of young pectus excavatum patients treated with the minimal invasive Nuss procedure. Study design: The study protocol is designed for a single center, prospective, unblinded, randomized clinical trial. Study population & intervention: Intercostal nerve cryoablation will be compared to thoracic epidural analgesia in young pectus excavatum patients (i.e., 12-24 years of age) treated with the minimal invasive Nuss procedure. Block randomization, including stratification based on age (12-16 years and 17-24 years) and sex, with an allocation ratio of 1:1 will be performed. Main study parameters/endpoints: Postoperative length of hospital stay will be recorded as the primary endpoint. Secondary outcomes include: 1) pain intensity; 2) operative time; 3) opioid usage; 4) procedure and analgesia-related complications, including neuropathic pain; 5) intensive care unit admissions; 6) readmissions; 7) postoperative mobility; 8) health related quality of Life; 9) days to return to work/school; 10) number of postoperative outpatient visits and 11) hospital costs. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The risks for study participants are negligible as the cryoablation technique has already been effectively used in the Nuss procedure without any serious side effects. Also, participants will be monitored daily by nursing staff and surgeons while admitted to the hospital. Burden associated with participation in the current study consists of completion of several questionnaires preoperatively and postoperatively.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pectus Excavatum, Funnel Chest
Keywords
Pectus Excavatum, Funnel Chest, Intercostal nerve cryoablation, Analgesia

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Single center, prospective, unblinded, randomized clinical trial. Block randomization, including stratification based on age (12-16 years and 17-24 years) and sex, with an allocation ratio of 1:1 will be performed.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
46 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intercostal nerve cryoablation
Arm Type
Experimental
Arm Description
When a patient is allocated to the intercostal nerve cryoablation group, cryoablation will be performed prior to bar placement. In brief, cryoablation will be performed at the level of the bar and two levels above and below, bilaterally. For this, a second portal access will be placed for video guidance on the contralateral side, and the cryoprobe (cryoICE, Atricure, Masion, OH, USA) will be inserted through the thoracic incisions that are already made for bar placement. The probe will be placed at the inferior aspect of the ribs, posterior to the midaxillary line, directly on the neurovascular bundle. One freezing cycle takes 2 minutes, and a temperature of -60 ⁰C will be applied. The probe will be warmed to room temperature before removing it from the pleura to prevent additional trauma. Furthermore, intercostal nerve cryoablation will be combined with single shot bupivacaine (1.25 mg/ml) intercostal nerve blocks placed just anterior to the side of the cryoablation.
Arm Title
Thoracic epidural (local continuous infusion with sufentanyl (1 µg/ml) and bupivacaine (1.25 mg/ml))
Arm Type
Active Comparator
Arm Description
Prior to surgery, an anesthesiologist will place the thoracic epidural at T5-T6 or T6-T7 interspace in the awake patient. After correct placement, a local continuous infusion with sufentanyl (1 µg/ml) and bupivacaine (1.25 mg/ml) will be started. At the third postoperative day, thoracic epidural analgesia will be ceased and transitioned to oral pain medication at discretion of the pain management team. In general, opioids (oxycodone with prolonged discharge 10 mg PO every 12 hours and oxycodone 5 mg every 6 hours as needed) will be provided 12 hours before thoracic epidural analgesia is ceased.
Intervention Type
Procedure
Intervention Name(s)
Intercostal nerve cryoablation
Other Intervention Name(s)
Cryoablation
Intervention Description
Intercostal nerve cryoablation is applied during Nuss procedure.
Intervention Type
Drug
Intervention Name(s)
Thoracic epidural analgesia (continuous infusion with sufentanyl (1 µg/ml) and bupivacaine (1.25 mg/ml))
Other Intervention Name(s)
Epidural
Intervention Description
Thoracic epidural is placed prior to Nuss procedure
Intervention Type
Drug
Intervention Name(s)
Intercostal nerve block (single shot bupivacaine (1.25 mg/ml))
Other Intervention Name(s)
Intercostal nerve block
Intervention Description
Single shot bupivacaine (1.25 mg/ml) intercostal nerve blocks are placed just anterior to the side of the cryoablation.
Intervention Type
Drug
Intervention Name(s)
Opioids (oxycodone with prolonged discharge 10 mg PO every 12 hours and oxycodone 5 mg every 6 hours, as needed)
Other Intervention Name(s)
opioids, oxycodone (with prolonged discharge)
Intervention Description
Opioids
Primary Outcome Measure Information:
Title
Length of hospital stay
Description
Number of days of hospital admittance after the Nuss procedure.
Time Frame
Hospitalization period, average of 5 days
Secondary Outcome Measure Information:
Title
Pain intensity
Description
Pain intensity at rest and during mobilization. Pain scores will be rated on the numeric rating scale (NRS, 1-10)
Time Frame
Preoperative care unit before surgery, in the morning on postoperative day 1 and 2, and 7 days, 14 days, 3 months and 6 months post operation
Title
Operative time
Description
Operative time in minutes. Duration of cryoablation will be assessed separately. Operative time will not include the time needed for the placement of the thoracic epidural as placement will be performed in the preoperative care unit.
Time Frame
During Nuss procedure
Title
Opioid usage
Description
A) Opioid usage during postoperative day 1 and 2; B) Opioid usage within the first 2 weeks after surgery. Opioid usage will be converted to oral morphine milligram equivalents (MME). Epidural infusion medication does not distribute systematically and therefore cannot be converted to MME. Epidural infusion medication will be omitted in calculation of opioid usage and opioid usage in the Thoracic epidural group will therefore be an underestimation of the actual usage. Upon discharge, patients will be prescribed opioids for 9 days. The need for a refill prescription will be assessed via a telephone appointment.
Time Frame
postoperative day 1 and 2, and first 2 weeks after surgery
Title
Procedure- and analgesia-related complications
Description
Procedure- and analgesia-related complications as defined in Supplementary Materials Table 1-2, including neuropathic pain, graded according to the Clavien-Dindo classification.
Time Frame
6 months postoperative
Title
Intensive care unit admission
Description
Intensive care unit admission due to the occurrence of perioperative complications in absolute numbers
Time Frame
Hospitalization period, average of 5 days
Title
Length of intensive care unit admission
Description
Length of admission due to the occurrence of perioperative complications in absolute numbers.
Time Frame
Hospitalization period, average of 5 days
Title
Number of readmissions
Description
Number of readmissions denoted as absolute numbers.
Time Frame
6 months postoperative
Title
Length of readmissions
Description
length of readmissions denoted as absolute numbers.
Time Frame
6 months postoperative
Title
Degree of mobility
Description
Degree of mobility measured on a 4-point scale (i.e., 1. on the bed, 2. to the chair, 3. to the toilet, 4. outside the patient's hospital room) during postoperative day 1 and 2.
Time Frame
Postoperative day 1 and 2
Title
HRQOL - PEEQ
Description
HRQOL, measured by the Dutch version of the pectus evaluation questionnaire (PEEQ). The PEEQ is a validated disease specific questionnaire evaluating the quality of life in pectus excavatum patients (37,38).
Time Frame
Before surgery as a baseline measurement, and at 2 weeks, 3 months and 6 months after the surgical procedure
Title
HRQOL - SF-36
Description
HRQOL, measured by the Dutch version of the short form health survey (SF-36)(37-40). The SF-36 is a generic questionnaire that taps health in eight dimensions (39).
Time Frame
Before surgery as a baseline measurement, and at 2 weeks, 3 months and 6 months after the surgical procedure
Title
HRQOL - EQ-5D-5L
Description
HRQOL, measured by the Dutch version of the EuroQol 5 dimensions 5 levels (EQ-5D-5L) (37-40). For the EQ-5D-5L, participants will rate their health in 5 dimensions on 5 levels and will give an overall score of their health on a visual analogue scale (VAS) (40).
Time Frame
Before surgery as a baseline measurement, and at 2 weeks, 3 months and 6 months after the surgical procedure
Title
Days to return to work/school
Description
Days to return to work/school, reported as days between discharge from hospital and return to work or school.
Time Frame
6 months postoperative
Title
Postoperative visits
Description
Number of postoperative outpatient visits and telephone appointments denoted as absolute numbers in the first 6 months after the surgical procedure.
Time Frame
6 months postoperative
Title
Hospital costs
Description
Hospital costs, reported as hospital costs during initial hospitalization (e.g., medication, patient care supply, surgical equipment), and hospital costs after discharge until 6 months follow-up (e.g., medications, outpatient visits, (opioid related) readmissions).
Time Frame
6 months postoperative

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
24 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients undergoing the minimal invasive Nuss procedure for surgical repair of pectus excavatum. Young patients (12-24 years of age) according to the definition used by the World Health Organization. This cut-off point is chosen to create a more homogenous patient sample, as the thoracic cage is fully matured by the age of 24, in size and density, which will have an effect on postoperative pain. Exclusion Criteria: A chest wall deformity other than pectus excavatum; Opioid use in the 3 months prior to surgery; Pain syndrome (e.g., fibromyalgia) or neuropathic pain prior to surgical repair of pectus excavatum; Connective tissue disease (e.g., Marfan syndrome, Ehlers-Danlos syndrome); Previous thoracic surgery or pectus excavatum repair; Contraindication for intercostal nerve cryoablation or thoracic epidural analgesia (e.g., patient refusal, infection at the site of cannulation, uncontrolled systemic infection, bleeding diathesis, increased intracranial pressure, mechanical spine obstruction); Psychiatric disease currently receiving treatment; Not mastering the Dutch language; Participation in another clinical trial that may interfere with the current trial.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Erik R De Loos
Phone
088-4597777
Email
e.deloos@zuyderland.nl
First Name & Middle Initial & Last Name or Official Title & Degree
Aimée Franssen
Phone
088-4597777
Email
ai.franssen@zuyderland.nl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Erik R De Loos
Organizational Affiliation
Zuyderland Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Zuyderland Medical Center
City
Heerlen
State/Province
Limburg
ZIP/Postal Code
6419 PC
Country
Netherlands
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Erik R De Loos, MD, PhD
Phone
088-4597777
Email
e.deloos@zuyderland.nl
First Name & Middle Initial & Last Name & Degree
Aimée JPM Franssen, PhD
First Name & Middle Initial & Last Name & Degree
Nicky Janssen, MD
First Name & Middle Initial & Last Name & Degree
Erik R De Loos, MD PhD

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
11877663
Citation
Croitoru DP, Kelly RE Jr, Goretsky MJ, Lawson ML, Swoveland B, Nuss D. Experience and modification update for the minimally invasive Nuss technique for pectus excavatum repair in 303 patients. J Pediatr Surg. 2002 Mar;37(3):437-45. doi: 10.1053/jpsu.2002.30851.
Results Reference
result
PubMed Identifier
18582827
Citation
Nuss D. Minimally invasive surgical repair of pectus excavatum. Semin Pediatr Surg. 2008 Aug;17(3):209-17. doi: 10.1053/j.sempedsurg.2008.03.003.
Results Reference
result
PubMed Identifier
20974443
Citation
Nuss D, Kelly RE Jr. Indications and technique of Nuss procedure for pectus excavatum. Thorac Surg Clin. 2010 Nov;20(4):583-97. doi: 10.1016/j.thorsurg.2010.07.002.
Results Reference
result
PubMed Identifier
31699436
Citation
Dekonenko C, Dorman RM, Duran Y, Juang D, Aguayo P, Fraser JD, Oyetunji TA, Snyder CL, Holcomb GW 3rd, Millspaugh DL, St Peter SD. Postoperative pain control modalities for pectus excavatum repair: A prospective observational study of cryoablation compared to results of a randomized trial of epidural vs patient-controlled analgesia. J Pediatr Surg. 2020 Aug;55(8):1444-1447. doi: 10.1016/j.jpedsurg.2019.09.021. Epub 2019 Oct 26.
Results Reference
result
PubMed Identifier
24682079
Citation
Qi J, Du B, Gurnaney H, Lu P, Zuo Y. A prospective randomized observer-blinded study to assess postoperative analgesia provided by an ultrasound-guided bilateral thoracic paravertebral block for children undergoing the Nuss procedure. Reg Anesth Pain Med. 2014 May-Jun;39(3):208-13. doi: 10.1097/AAP.0000000000000071.
Results Reference
result
PubMed Identifier
35817669
Citation
Sertcakacilar G, Kose S. Bilateral PECS II Block is Associated with Decreased Opioid Consumption and Reduced Pain Scores for up to 24 hours After Minimally Invasive Repair of Pectus Excavatum (Nuss Procedure): A Retrospective Analysis. J Cardiothorac Vasc Anesth. 2022 Oct;36(10):3833-3840. doi: 10.1053/j.jvca.2022.06.001. Epub 2022 Jun 6.
Results Reference
result
PubMed Identifier
31784472
Citation
Abdel Shaheed C, McLachlan AJ, Maher CG. Rethinking "long term" opioid therapy. BMJ. 2019 Nov 29;367:l6691. doi: 10.1136/bmj.l6691. No abstract available.
Results Reference
result
PubMed Identifier
32166917
Citation
Cadaval Gallardo C, Martinez J, Bellia-Munzon G, Nazar M, Sanjurjo D, Toselli L, Martinez-Ferro M. Thoracoscopic cryoanalgesia: A new strategy for postoperative pain control in minimally invasive pectus excavatum repair. Cir Pediatr. 2020 Jan 20;33(1):11-15. English, Spanish.
Results Reference
result
PubMed Identifier
33199059
Citation
Aiken TJ, Stahl CC, Lemaster D, Casias TW, Walker BJ, Nichol PF, Leys CM, Abbott DE, Brinkman AS. Intercostal nerve cryoablation is associated with lower hospital cost during minimally invasive Nuss procedure for pectus excavatum. J Pediatr Surg. 2021 Oct;56(10):1841-1845. doi: 10.1016/j.jpedsurg.2020.10.009. Epub 2020 Oct 19.
Results Reference
result
PubMed Identifier
29672193
Citation
Morikawa N, Laferriere N, Koo S, Johnson S, Woo R, Puapong D. Cryoanalgesia in Patients Undergoing Nuss Repair of Pectus Excavatum: Technique Modification and Early Results. J Laparoendosc Adv Surg Tech A. 2018 Sep;28(9):1148-1151. doi: 10.1089/lap.2017.0665. Epub 2018 Apr 19.
Results Reference
result
PubMed Identifier
30278932
Citation
Harbaugh CM, Johnson KN, Kein CE, Jarboe MD, Hirschl RB, Geiger JD, Gadepalli SK. Comparing outcomes with thoracic epidural and intercostal nerve cryoablation after Nuss procedure. J Surg Res. 2018 Nov;231:217-223. doi: 10.1016/j.jss.2018.05.048. Epub 2018 Jun 21.
Results Reference
result
PubMed Identifier
33853732
Citation
Sun RC, Mehl SC, Anbarasu CR, Portuondo JI, Espinoza AF, Whitlock R, Mazziotti MV. Intercostal cryoablation during Nuss procedure: A large volume single surgeon's experience and outcomes. J Pediatr Surg. 2021 Dec;56(12):2229-2234. doi: 10.1016/j.jpedsurg.2021.03.006. Epub 2021 Mar 17.
Results Reference
result
PubMed Identifier
29927703
Citation
Sujka J, Benedict LA, Fraser JD, Aguayo P, Millspaugh DL, St Peter SD. Outcomes Using Cryoablation for Postoperative Pain Control in Children Following Minimally Invasive Pectus Excavatum Repair. J Laparoendosc Adv Surg Tech A. 2018 Nov;28(11):1383-1386. doi: 10.1089/lap.2018.0111. Epub 2018 Jun 21.
Results Reference
result
PubMed Identifier
32929487
Citation
Daemen JHT, de Loos ER, Vissers YLJ, Bakens MJAM, Maessen JG, Hulsewe KWE. Intercostal nerve cryoablation versus thoracic epidural for postoperative analgesia following pectus excavatum repair: a systematic review and meta-analysis. Interact Cardiovasc Thorac Surg. 2020 Oct 1;31(4):486-498. doi: 10.1093/icvts/ivaa151.
Results Reference
result
PubMed Identifier
30935731
Citation
Graves CE, Moyer J, Zobel MJ, Mora R, Smith D, O'Day M, Padilla BE. Intraoperative intercostal nerve cryoablation During the Nuss procedure reduces length of stay and opioid requirement: A randomized clinical trial. J Pediatr Surg. 2019 Nov;54(11):2250-2256. doi: 10.1016/j.jpedsurg.2019.02.057. Epub 2019 Mar 17.
Results Reference
result
PubMed Identifier
31760443
Citation
Zobel MJ, Ewbank C, Mora R, Idowu O, Kim S, Padilla BE. The incidence of neuropathic pain after intercostal cryoablation during the Nuss procedure. Pediatr Surg Int. 2020 Mar;36(3):317-324. doi: 10.1007/s00383-019-04602-1. Epub 2019 Nov 23.
Results Reference
result
Links:
URL
https://www.atricure.com/sites/default/files/pdf-doc/K200697.Letter.SE_.FINAL_Sent001.pdf
Description
FDA
URL
https://www.atricure.com/sites/default/files/pdf-doc/PM-US-0058D-0224-G_cryoSPHERE_Brochure.pdf
Description
Product brochure

Learn more about this trial

Intercostal Nerve Cryoablation Versus Epidural Analgesia for Nuss Repair of Pectus Excavatum

We'll reach out to this number within 24 hrs